These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 34819266)

  • 1. Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial.
    Heymach JV; Mitsudomi T; Harpole D; Aperghis M; Jones S; Mann H; Fouad TM; Reck M
    Clin Lung Cancer; 2022 May; 23(3):e247-e251. PubMed ID: 34819266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
    Senan S; Okamoto I; Lee GW; Chen Y; Niho S; Mak G; Yao W; Shire N; Jiang H; Cho BC
    Clin Lung Cancer; 2020 Mar; 21(2):e84-e88. PubMed ID: 31948903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
    Heymach JV; Harpole D; Mitsudomi T; Taube JM; Galffy G; Hochmair M; Winder T; Zukov R; Garbaos G; Gao S; Kuroda H; Ostoros G; Tran TV; You J; Lee KY; Antonuzzo L; Papai-Szekely Z; Akamatsu H; Biswas B; Spira A; Crawford J; Le HT; Aperghis M; Doherty GJ; Mann H; Fouad TM; Reck M;
    N Engl J Med; 2023 Nov; 389(18):1672-1684. PubMed ID: 37870974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
    Hui R; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Gray JE; Rydén A; Viviers L; Poole L; Zhang Y; Dennis PA; Antonia SJ
    Lancet Oncol; 2019 Dec; 20(12):1670-1680. PubMed ID: 31601496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial.
    Lu S; Zhang W; Wu L; Wang W; Zhang P; ; Fang W; Xing W; Chen Q; Yang L; Mei J; Tan L; Sun X; Xu S; Hu X; Yu G; Yu D; Yang N; Chen Y; Shan J; Xing L; Tian H; Zhang X; Zhou M; Fang H; Wu G; Liu Y; Ye M; Cao L; Jiang J; Li X; Zhu L; Li D; Kang M; Zhong A; Chen K; Wu N; Sun Q; Ma H; Cai K; Wang C; Lin G; Zhu K; Zhang Y; Zhang X; Hu H; Zhang W; Chen J; Yang Z; Hang X; Hu J; Huang Y; Zhang Z; Zhang L; Zhang L; Liu L; Lin D; Zhang J; Chen G; Li Y; Zhu L; Wang W; Yu W; Cao D; Keegan P; Yao S
    JAMA; 2024 Jan; 331(3):201-211. PubMed ID: 38227033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.
    Altorki NK; McGraw TE; Borczuk AC; Saxena A; Port JL; Stiles BM; Lee BE; Sanfilippo NJ; Scheff RJ; Pua BB; Gruden JF; Christos PJ; Spinelli C; Gakuria J; Uppal M; Binder B; Elemento O; Ballman KV; Formenti SC
    Lancet Oncol; 2021 Jun; 22(6):824-835. PubMed ID: 34015311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.
    Naidoo J; Antonia S; Wu YL; Cho BC; Thiyagarajah P; Mann H; Newton M; Faivre-Finn C
    J Thorac Oncol; 2023 May; 18(5):657-663. PubMed ID: 36841540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
    Rothschild SI; Zippelius A; Eboulet EI; Savic Prince S; Betticher D; Bettini A; Früh M; Joerger M; Lardinois D; Gelpke H; Mauti LA; Britschgi C; Weder W; Peters S; Mark M; Cathomas R; Ochsenbein AF; Janthur WD; Waibel C; Mach N; Froesch P; Buess M; Bohanes P; Godar G; Rusterholz C; Gonzalez M; Pless M;
    J Clin Oncol; 2021 Sep; 39(26):2872-2880. PubMed ID: 34251873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy.
    Filippi AR; Dziadziuszko R; García Campelo MR; Paoli JB; Sawyer W; Díaz Pérez IE
    Future Oncol; 2021 Dec; 17(34):4657-4663. PubMed ID: 34775804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress).
    Kaira K; Mouri A; Kato S; Yoshimura K; Kagamu H; Kobayashi K
    BMC Cancer; 2020 Oct; 20(1):961. PubMed ID: 33023530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy.
    Bardia A; Pusztai L; Albain K; Ciruelos EM; Im SA; Hershman D; Kalinsky K; Isaacs C; Loirat D; Testa L; Tokunaga E; Wu J; Dry H; Barlow W; Kozarski R; Maxwell M; Harbeck N; Sharma P
    Ther Adv Med Oncol; 2024; 16():17588359241248336. PubMed ID: 38686016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.
    De Ruysscher D; Ramalingam S; Urbanic J; Gerber DE; Tan DSW; Cai J; Li A; Peters S
    Clin Lung Cancer; 2022 May; 23(3):e264-e268. PubMed ID: 34489161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.
    Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S
    JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.
    Senan S; Özgüroğlu M; Daniel D; Villegas A; Vicente D; Murakami S; Hui R; Faivre-Finn C; Paz-Ares L; Wu YL; Mann H; Dennis PA; Antonia SJ
    ESMO Open; 2022 Apr; 7(2):100410. PubMed ID: 35247871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
    Rizvi NA; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; van den Heuvel MM; Cobo M; Vicente D; Smolin A; Moiseyenko V; Antonia SJ; Le Moulec S; Robinet G; Natale R; Schneider J; Shepherd FA; Geater SL; Garon EB; Kim ES; Goldberg SB; Nakagawa K; Raja R; Higgs BW; Boothman AM; Zhao L; Scheuring U; Stockman PK; Chand VK; Peters S;
    JAMA Oncol; 2020 May; 6(5):661-674. PubMed ID: 32271377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review.
    Christopoulos P
    Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
    Antonia SJ; Villegas A; Daniel D; Vicente D; Murakami S; Hui R; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Bourhaba M; Quantin X; Tokito T; Mekhail T; Planchard D; Kim YC; Karapetis CS; Hiret S; Ostoros G; Kubota K; Gray JE; Paz-Ares L; de Castro Carpeño J; Wadsworth C; Melillo G; Jiang H; Huang Y; Dennis PA; Özgüroğlu M;
    N Engl J Med; 2017 Nov; 377(20):1919-1929. PubMed ID: 28885881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer.
    Jabbour SK; Cho BC; Bria E; Kato T; Bhosle J; Gainor JF; Reguart N; Wang L; Morgensztern D; Shentu Y; Kim SJ; Souza F; Reck M
    Clin Lung Cancer; 2022 Sep; 23(6):e342-e346. PubMed ID: 35618629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study.
    Park S; Sun JM; Choi YL; Oh D; Kim HK; Lee T; Chi SA; Lee SH; Choi YS; Jung SH; Ahn MJ; Ahn YC; Park K; Shim YM
    ESMO Open; 2022 Feb; 7(1):100385. PubMed ID: 35158205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.